186 386

Cited 0 times in

Oral Administration of Memantine Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Joo, IS; Hwang, DH; Seok, JI; Shin, SK; Kim, SU
Journal of clinical neurology (Seoul, Korea), 3(4):181-186, 2007
Journal Title
Journal of clinical neurology (Seoul, Korea)
Background and Purpose: N-methyl-D-aspartate (NMDA)-mediated neurotoxicity and oxidative stress have been implicated in the etiology of amyotrophic lateral sclerosis (ALS). Memantine is a low-affinity, noncompetitive NMDA receptor antagonist that may protect against motor neuron degeneration.

Methods: Thirty transgenic mice expressing the G93A SOD1 mutation were randomly divided into control, lowdose memantine (30 mg/kg/day), and high-dose memantine (90 mg/kg/day) groups, with memantine supplied daily with drinking water beginning at 75 days of age. Body weight, survival, and behavioral performances including a rotarod test, paw grip endurance, and hindlimb extension reflex were assessed in the control and memantine-diet groups.

Results: Clinical symptoms were evident in the G93A transgenic mice by 11 weeks of age. Memantine was tolerated well. Compared to control, mice treated with memantine performed better in the rotarod test and hindlimb extension reflex. Moreover, low-dose memantine treatment significantly prolonged the survival of the transgenic mice relative to control mice (141 vs 134 days, p<0.05).

Conclusion: These findings suggest that memantine, even when administered at the time of symptom onset, has beneficial effects on patients with ALS.
Amyotrophic lateral sclerosisMemantineN-methyl-D-aspartate receptor antagonist
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurology
AJOU Authors
주, 인수
Full Text Link
Files in This Item:
Journal of clinical neurology_3(4)_181-186.pdfDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.